Francis E. Marchlinski, MD, FACC
Director, Electrophysiology; Prof of Medcine

Printed as of 9/7/2026

Disclosures

Personal Commercial (6)

Company Name	Relationship Category	Compensation Level	*Topic Area(s)*
Self			
Abbott Laboratories	Consultant Fees/Honoraria	Significant (>= $5,000)	*Arrhythmias and Clinical EP Other*
Abbott Laboratories (SJM)	Consultant Fees/Honoraria	Modest (< $5,000)	*Arrhythmias and Clinical EP Other*
Biosense Webster Inc	Consultant Fees/Honoraria	Modest (< $5,000)	*Arrhythmias and Clinical EP*
Biotronik	Consultant Fees/Honoraria	Significant (>= $5,000)	*Arrhythmias and Clinical EP*
Boston Scientific	Consultant Fees/Honoraria	Significant (>= $5,000)	*Arrhythmias and Clinical EP*
Medtronic	Consultant Fees/Honoraria	Modest (< $5,000)	*Arrhythmias and Clinical EP*

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (4)

Year	Case Title	Represented	Description	Compensation
Self				
2024	endocarditis	Defendant *† no commercial funding*	Patient developed endocarditis that was not diagnosed on initial consultation by cardiologist. Consultant, case ongoing.	Modest (< $5,000)
2023	Atrial esophageal fistula	Defendant *† no commercial support*	3 weeks post ablation developed neurologic symptoms and found to have atrial esopageal fistula. Consultant, no deposition or trial. Case settled.	Modest (< $5,000)
2021	cerebral vascular accident	Plaintiff *† no commercial funding*	suffered CVA off anticoagulation x 2 weeks. History of paroxysmal atrial fibrillation, s/p ablation. Consultant, no deposition or trial.	Modest (< $5,000)
2021	Cardiomyopathy and bradycardia	Defendant *† no commercial funding*	patient with recurrent syncope and cardiomyopathy suffered cardiac arrest	Significant (>= $5,000)

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 12/4/2023
URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 12/4/2023
URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 12/4/2023
URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 3/18/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.